Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Lumenis Eye-Treatment Products Approved
Oct 2002
SANTA CLARA, Calif., Oct. 18 -- Lumenis Ltd. announced this week that two of its products have received marketing clearance from the US Food & Drug Administration (FDA); its Novus Varia multicolor photocoagulation laser system was approved for the treatment of a variety of retinal diseases, and its Selecta Duet combination laser system was cleared for treating open angle and angle closure glaucoma as well as secondary cataracts.

After the announcement of FDA for clearance of the photocoagulation laser system, shares of the Yokneam, Israel-based company closed Tuesday at $4.37, up 69 cents, or nearly 19 percent, on Nasdaq. Lumenis reported sales of $315.2 million last year.

Lumenis said the photocoagulation laser system is the first diode laser to offer the spectrum of green, yellow and red light in one standard platform. The FDA approved the laser to treat eye problems such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinopathy of prematurity and retinal vein occlusions.

The Selecta Duet integrates the Lumenis patented selective laser trabeculoplasty platform with advanced photodisruptor Nd:YAG laser technology.

For more information, visit:

News & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.